JPRN-UMIN000000492
Completed
未知
Concurrent Treatment of Cardiovascular Disease in Peritoneal Dialysis (PD) patients. Multi-center Randomized Clinical Study with Aldosterone blockade (spironolactone) and Angiotensin Receptor Blocker (ARB) or Angiotensin-Converting-Enzyme Inhibitor (ACEI). - MCS/AA
agoya University0 sites160 target enrollmentOctober 1, 2006
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- End-Stage Renal Disease (ESRD) and Cardio-Vascular Disease (CVD)
- Sponsor
- agoya University
- Enrollment
- 160
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Should be excluded even if one of them would be positive; Patients under 18, older than 80\. Patients with anemia whose Hb is less than 9 g/dl. Patients treated for more than 5 years after initiation of dialysis. Patients with heart failure of NYHA III, IV. Patients with pregnancy or the suspected. Patients treated with acid\-base fluid dialysis.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Cohort Study on Treatment of Cardiovascular Diseases with Traditional Chinese MedicineCardiovascular DiseasesITMCTR2200005811Tianjin University of Traditional Chinese Medicine
Completed
Not Applicable
Cardiac- and vascular disease (-abnormalities) as underlying cause of premature birth.premature birth100103941001027310003216NL-OMON39237Academisch Medisch Centrum300
Recruiting
Phase 3
ong term impact of RAS inhibition on cardio-renal outcomes: a comparative trial of angiotensin converting enzyme inhibitors, angiotensin receptor blockers or combined therapy with both agents in patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.Cardiovascular - Normal development and function of the cardiovascular systemMetabolic and Endocrine - DiabetesACTRN12607000333415Consorzio Mario Negri Sud2,100
Active, not recruiting
Phase 1
Treatment of heart and blood vessel disease (cardiovascular disease) with low dose blood thinner (low dose rivaroxaban) in people with advanced kidney disease or receiving dialysis (advanced chronic kidney disease).Improvement of cardiovascular outcomes in patients with advancedchronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]CTIS2024-512483-59-00The George Institute For Global Health2,000
Not yet recruiting
Not Applicable
Cardiovascular disease manifestations in COVID-19 patientsHealth Condition 1: B99-B99- Other infectious diseasesHealth Condition 2: B338- Other specified viral diseasesCTRI/2021/06/034065Dr Swati Datta